CalciMedica (CALC) Drops -27% Over 30 Days Amid Biotech Headwinds
Key Takeaways
- CalciMedica (CALC) shares fell roughly 27% over the trailing 30 days, sliding from about $2.32 to near $1.70.
- The decline extended a prolonged multi-month downtrend and followed a 1-for-5 reverse stock split completed in late August.
- Losses came despite a Buy initiation from Guggenheim and FDA alignment on the Phase 2b Auxora trial design, underscoring lingering financing and dilution concerns.
- As a pre-revenue, clinical-stage biotechnology company, CALC remains highly sensitive to cash runway, clinical milestones, and broader risk appetite.
CalciMedica (CALC) Business Overview
CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California. It focuses on therapies that inhibit calcium release-activated calcium (CRAC) channels to help regulate immune responses and reduce tissue damage in inflammatory and immunologic diseases. The lead program, Auxora (zegocractin, formerly CM4620), targets acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury. A second candidate, CM5480, is an oral CRAC inhibitor under evaluation for pulmonary arterial hypertension (PAH).
With no approved products and no product revenue, the company sits squarely in the early-stage biotech category. Its modest market capitalization and concentrated pipeline mean investor attention centers on clinical data readouts, regulatory steps, and the ability to secure ongoing funding.
Stock Performance Over the Past 30 Days and Quarter
In the trailing 30 days, CALC declined approximately 27%, moving from a close near $2.32 to roughly $1.70. The slide occurred gradually through September rather than in one abrupt move. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a split-adjusted basis, the quarterly picture shows even steeper losses. The shares traded near $4.90 in late June before reaching about $1.70 by late September, a drop of roughly 65%. This longer-term weakness aligns with the limited cash generation typical of a pre-revenue developer.
Drivers of the Recent 30-Day Decline
Multiple elements weighed on the stock. The company executed a 1-for-5 reverse stock split in late August, a common move to meet exchange listing requirements and lift the per-share price. Shares continued lower afterward, suggesting the action did not alter underlying selling pressure.
Financial fundamentals stayed challenging. CalciMedica posted no product revenue and recorded a net loss, as expected for its stage, while maintaining a modest cash balance relative to development needs. This environment keeps dilution and financing concerns prominent in investor thinking.
Positive updates arrived anyway. Guggenheim started coverage with a Buy rating focused on CM5480 potential, and the company confirmed FDA alignment on endpoints and patient population for the Phase 2b Auxora trial. That the stock still declined highlights the impact of risk-off sentiment toward speculative micro-cap biotechs and thinner trading volumes.
Quarterly Context and Broader Pressures
The wider quarterly drop reflects a clinical-stage company navigating both operational and capital-market realities. Second-quarter 2026 results, released in August, showed ongoing losses consistent with the development phase. The reverse split added technical and psychological weight, as post-split shares in lagging small caps often drift lower.
Small- and micro-cap biotechnology names have faced a tough backdrop overall, with investors seeking clearer clinical progress and financing stability. For CalciMedica, the lack of near-term revenue and reliance on future capital raises sustained the downtrend despite isolated pipeline positives. From what I see, this pattern is common in the sector right now.
Key Items to Watch Going Forward
Attention will likely stay on clinical execution and balance-sheet strength. Investors should track enrollment and data from the CARPO Phase 2b trial in acute pancreatitis, the investigator-initiated CRSPA study in pediatric asparaginase-induced pancreatic toxicity, and advancement of CM5480 in pulmonary arterial hypertension. An update on the CRSPA program is expected during 2026.
Financing considerations remain central, given the cash position relative to development timelines. Upcoming quarterly results, anticipated around November 2026, and any shifts in analyst coverage will also influence sentiment. As with all clinical-stage biotechs, outcomes carry inherent uncertainty, and both pipeline potential and liquidity risks deserve careful evaluation.
Insights from Tickeron Tools
I’ve found Tickeron’s Trending AI Robots page helpful when reviewing volatile names like this one. It highlights a selection of AI-powered trading bots actively operating across the market, with only top performers featured. These bots offer different strategies and timeframes, supplying a quantitative angle on activity that complements traditional analysis. Explore the Trending AI Robots page to see the current lineup and performance details.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CALC's Stochastic Oscillator is staying in oversold zone for 17 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +10.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CALC advanced for three days, in 186 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for CALC moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 25 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CALC as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CALC turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
CALC moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CALC crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CALC broke above its upper Bollinger Band on August 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CALC entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.167) is normal, around the industry mean (26.453). P/E Ratio (0.297) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. CALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement